Posted by Michael Wonder on 06 Aug 2021
Novavax delays Covid vaccine emergency authorisation submission to FDA until fourth quarter
5 August 2021 - The company says it is still on track to produce 100 million doses per month by the end of the third quarter and 150 million per month by the end of the fourth quarter.
Novavax announced that it will delay the submission of its COVID-19 vaccine to the FDA for emergency use authorisation until its fourth quarter.
